Generic Drug News and Research RSS Feed - Generic Drug News and Research

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Rite Aid's fourth quarter revenues increase 2.2% to $6.6 billion

Rite Aid Corporation today reported operating results for its fourth quarter and fiscal year ended March 1, 2014. [More]

FDA approves Teva Pharmaceutical's Generic Lovaza Capsules

Teva Pharmaceutical Industries Ltd. announces the approval of the generic equivalent to Lovaza® (Omega-3-Acid Ethyl Esters Capsules, USP), in the United States. [More]

Walgreens' March sales up 4.5% to $6.43 billion

Walgreens had March sales of $6.43 billion, an increase of 4.5 percent from $6.16 billion for the same month in fiscal 2013. [More]

Viewpoints: 'Thrice-buried' Obamacare 'looks very much alive;' Ted Cruz 'gets an earful'

Back when rate shock, website problems and lagging enrollment were threatening to unravel the new health care law before it fully took effect, I concluded a column on Obamacare's repeated near-death experiences with the following warning to conservatives: ... What isn't killed outright grows stronger the longer it's embedded in the federal apparatus, gaining constituents and interest-group support just by virtue of its existence even if it doesn't work out the way it was designed. ... the serious right-of-center alternatives to Obamacare have always included policies to expand coverage, and with a coverage expansion accomplished, Republicans may find themselves effectively forced in a more serious direction. ... wherever they go and whatever they do, they will have to deal with the reality that Obamacare, thrice-buried, looks very much alive (Ross Douthat, 3/31). [More]
U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company's COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the "'808 patent"). [More]
Research report on China's duloxetine market

Research report on China's duloxetine market

Research and Markets has announced the addition of the "Investigation Report on China Duloxetine Market" report to their offering. [More]
Research report on China's bevacizumab market

Research report on China's bevacizumab market

Research and Markets has announced the addition of the "Investigation Report on China Bevacizumab Market, 2009-2018" report to their offering. [More]
Concise analysis of China’s rituximab drug market

Concise analysis of China’s rituximab drug market

Research and Markets has announced the addition of the "Investigation Report on China Rituximab Market, 2009-2018" report to their offering. [More]
China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2013. [More]

CPhI to conduct the 4th NEXTGEN China 2014 Conference from March 27 to 28

In March 2012, the 1st Nextgen China was held successfully in Shanghai. FDA, USP, national institutes for Food and Drug Control and leading pharmaceutical companies from home and abroad were invited to give presentations. [More]

Teva launches generic Xeloda Tablets in the U.S.

Teva Pharmaceutical Industries Ltd. announces the launch of the generic equivalent to Xeloda (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda is marketed by Genentech in the United States. [More]

Researchers identify communication strategies aimed at creating risk perceptions about generic drugs

Although there is widespread consensus among the scientific community that the composition of generic drugs is identical to that of brand name drugs, this is not the case among the public. [More]

Akorn's consolidated revenue for fourth quarter 2013 increases 19% to $85 million

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for the fourth quarter and year-ended December 31, 2013. [More]
Viewpoints: The evolution of Medicare; generic drugs and patient safety; new food labels

Viewpoints: The evolution of Medicare; generic drugs and patient safety; new food labels

About half a century ago, organized medicine and the hospital industry in this country struck a deal with Congress that in retrospect seems as audacious as it seems incredible: Congress was asked to surrender to these industries the keys to the United States Treasury. In return, the industries would allow Congress to pass a 1965 amendment to the Social Security Act .... We have come to know it as Medicare. [More]

First Edition: February 18, 2014

Kaiser Health News staff writer Jay Hancock, working in collaboration with USA Today, reports: "Congratulations. You bought insurance through one of the online Affordable Care Act exchanges, possibly after days or weeks of trying to get the site to work. Don't relax. Joining the plan is only the first challenge. Now you have to understand it. Policies sold through the online portals -- to more than 3 million people so far -- cover essential benefits and put a cap on your out-of-pocket medical costs. But you need to follow the rules" (Hancock, 2/17). [More]
FDA grants full approval of SYNRIBO for injection

FDA grants full approval of SYNRIBO for injection

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has granted full approval of SYNRIBO (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requirements set forth by the FDA. [More]

Cambrex fourth quarter sales increase 46.3% to $103 million

Cambrex Corporation reports results for the fourth quarter and full year ended December 31, 2013. [More]

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved the Company's supplemental new drug application for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE. [More]

Myelin Repair Foundation enters into agreement with NIH to assess MRF-008 for multiple sclerosis

The Myelin Repair Foundation today announced it has entered a Cooperative Research and Development Agreement with the National Institutes of Health to assess MRF-008, as a potential therapeutic for multiple sclerosis. This CRADA will facilitate collaboration between the MRF and National Institute of Neurological Disorders and Stroke at the NIH Clinical Center to study MRF-008, a drug identified by the MRF as a potential neuroprotective therapeutic to enhance repair in multiple sclerosis patients. [More]
Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). [More]